AMRN • NASDAQ
Amarin Corporation plc
$1.92
After Hours:
$1.90
(1.04%)-0.020
Closed: Jun 24, 7:21:59 PM GMT-4 · USD · NASDAQ · Disclaimer
StockUS listed securityIE headquartered
Previous close
$1.99
Day range
$1.90 - $2.01
Year range
$1.11 - $5.97
Market cap
762.26M USD
Avg Volume
4.44M
P/E ratio
-
Dividend yield
-
Financials
Income Statement
Financial performance
Revenue
Net income
(USD)Mar 2022Y/Y change
Revenue
94.63M-33.44%
Operating expense
100.70M-12.57%
Net income
-31.56M-1,841.14%
Earnings per share
-0.08
EBITDA
-27.53M-3,256.95%
Effective tax rate
-11.33%
Financial performance
Total assets
Total liabilities
(USD)Mar 2022Y/Y change
Cash and short-term investments
362.56M-29.56%
Total assets
973.71M-1.67%
Total liabilities
332.60M-6.48%
Total equity
641.11M
Shares outstanding
397.01M
Price to book
1.23
Return on assets
-6.93%
Return on capital
-10.64%
Financial performance
Net change in cash
(USD)Mar 2022Y/Y change
Net income
-31.56M-1,841.14%
Cash from operations
-98.85M-428.48%
Cash from investing
99.05M-22.58%
Cash from financing
-505.00K90.28%
Net change in cash
-303.00K-100.29%
Free cash flow
-65.57M-820.28%
About
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa, a prescription grade omega-3 fatty acid. In July 2012, their lead-candidate drug named Vascepa received FDA-approval, competing against GlaxoSmithKline's Lovaza. Wikipedia
Founded
1993
Employees
560
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for